Cumberland Pharmaceuticals (NASDAQ: CPIX) is one of 485 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Cumberland Pharmaceuticals to similar companies based on the strength of its institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.
Volatility & Risk
Cumberland Pharmaceuticals has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals’ peers have a beta of 1.08, indicating that their average share price is 8% more volatile than the S&P 500.
Institutional and Insider Ownership
34.7% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 46.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 39.5% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Cumberland Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cumberland Pharmaceuticals Competitors||-3,094.17%||-156.12%||-27.37%|
This is a summary of recent ratings and price targets for Cumberland Pharmaceuticals and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cumberland Pharmaceuticals Competitors||2771||8542||21394||570||2.59|
Cumberland Pharmaceuticals currently has a consensus price target of $9.25, indicating a potential upside of 42.09%. As a group, “Pharmaceutical preparations” companies have a potential upside of 45.58%. Given Cumberland Pharmaceuticals’ peers higher probable upside, analysts plainly believe Cumberland Pharmaceuticals has less favorable growth aspects than its peers.
Earnings & Valuation
This table compares Cumberland Pharmaceuticals and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cumberland Pharmaceuticals||$41.15 million||-$7.97 million||-93.00|
|Cumberland Pharmaceuticals Competitors||$2.03 billion||$132.98 million||-3.53|
Cumberland Pharmaceuticals’ peers have higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Cumberland Pharmaceuticals peers beat Cumberland Pharmaceuticals on 7 of the 13 factors compared.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. It marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. Its pre-approval products consist of Methotrexate injection for treating active rheumatoid, juvenile idiopathic, and psoriatic arthritis, as well as disabling psoriasis; and Totect injection for emergency oncology intervention, which helps to reverse the toxic effects of anthracycline chemotherapy in case of extravasation. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc, Nordic Group B.V., and Cumberland Emerging Technologies. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.